Grace Shinn, Karen Berger, David Roh, Kevin Doyle, Amelia K Boehme, Edward Sander Connolly, Soojin Park, Sachin Agarwal, Jan Claassen, Caroline Der-Nigoghossian
{"title":"接受皮下注射肝素预防治疗的神经重症患者的活性部分凝血活酶时间与抗因子 Xa 检测之间的一致性。","authors":"Grace Shinn, Karen Berger, David Roh, Kevin Doyle, Amelia K Boehme, Edward Sander Connolly, Soojin Park, Sachin Agarwal, Jan Claassen, Caroline Der-Nigoghossian","doi":"10.1177/19418744231159917","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Laboratory monitoring is not recommended when subcutaneous unfractionated heparin (SQ-UFH) is administered at prophylactic doses. However, aPTT prolongation and associated hemorrhage has been reported in the neurocritically ill. At our institution, Neuroscience Intensive Care Unit (Neuro-ICU) patients with prolonged aPTT are further evaluated with a follow up aPTT and anti-factor Xa.</p><p><strong>Purpose: </strong>The purpose of this study was to describe concordance between aPTT and anti-factor Xa in neurocritically ill patients receiving prophylactic SQ-UFH with evidence of aPTT prolongation.</p><p><strong>Methods: </strong>A retrospective chart review of adult patients admitted to the Neuro-ICU from June 2017 to June 2019 was performed. Patients were included if they received SQ-UFH with aPTT levels and at least one anti-factor Xa level drawn within one hour of each other. Concordance between paired aPTT and anti-factor Xa was evaluated using Cohen's weighted kappa.</p><p><strong>Results: </strong>Forty two patients with 56 paired aPTT and anti-factor Xa levels were included. The most prescribed SQ-UFH regimen was 5000 units every 8 hours (60.7%) and anti-factor Xa levels were drawn a median (IQR) of 5.7 (3.1-10.7) hours after the SQ-UFH dose. Only 16 (28.6%) pairs were in concordance. The analysis showed a weighted kappa of .09; 95% CI [-.05 to .22] indicating poor agreement.</p><p><strong>Conclusions: </strong>In neurocritically ill patients receiving prophylactic SQ-UFH with aPTT prolongation, there was poor concordance between aPTT and anti-factor Xa. This suggests that aPTT prolongation may not be solely driven by heparin activity and further evaluation of mechanistic drivers for coagulopathy in this population is necessary.</p>","PeriodicalId":46355,"journal":{"name":"Neurohospitalist","volume":"13 3","pages":"221-227"},"PeriodicalIF":0.9000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334062/pdf/","citationCount":"0","resultStr":"{\"title\":\"Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis.\",\"authors\":\"Grace Shinn, Karen Berger, David Roh, Kevin Doyle, Amelia K Boehme, Edward Sander Connolly, Soojin Park, Sachin Agarwal, Jan Claassen, Caroline Der-Nigoghossian\",\"doi\":\"10.1177/19418744231159917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Laboratory monitoring is not recommended when subcutaneous unfractionated heparin (SQ-UFH) is administered at prophylactic doses. However, aPTT prolongation and associated hemorrhage has been reported in the neurocritically ill. At our institution, Neuroscience Intensive Care Unit (Neuro-ICU) patients with prolonged aPTT are further evaluated with a follow up aPTT and anti-factor Xa.</p><p><strong>Purpose: </strong>The purpose of this study was to describe concordance between aPTT and anti-factor Xa in neurocritically ill patients receiving prophylactic SQ-UFH with evidence of aPTT prolongation.</p><p><strong>Methods: </strong>A retrospective chart review of adult patients admitted to the Neuro-ICU from June 2017 to June 2019 was performed. Patients were included if they received SQ-UFH with aPTT levels and at least one anti-factor Xa level drawn within one hour of each other. Concordance between paired aPTT and anti-factor Xa was evaluated using Cohen's weighted kappa.</p><p><strong>Results: </strong>Forty two patients with 56 paired aPTT and anti-factor Xa levels were included. The most prescribed SQ-UFH regimen was 5000 units every 8 hours (60.7%) and anti-factor Xa levels were drawn a median (IQR) of 5.7 (3.1-10.7) hours after the SQ-UFH dose. Only 16 (28.6%) pairs were in concordance. The analysis showed a weighted kappa of .09; 95% CI [-.05 to .22] indicating poor agreement.</p><p><strong>Conclusions: </strong>In neurocritically ill patients receiving prophylactic SQ-UFH with aPTT prolongation, there was poor concordance between aPTT and anti-factor Xa. This suggests that aPTT prolongation may not be solely driven by heparin activity and further evaluation of mechanistic drivers for coagulopathy in this population is necessary.</p>\",\"PeriodicalId\":46355,\"journal\":{\"name\":\"Neurohospitalist\",\"volume\":\"13 3\",\"pages\":\"221-227\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334062/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurohospitalist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/19418744231159917\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/4/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurohospitalist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19418744231159917","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:以预防性剂量使用皮下注射非分数肝素(SQ-UFH)时,不建议进行实验室监测。但有报道称,神经重症患者的 aPTT 会延长并伴有出血。在我院,神经科学重症监护病房(Neuro-ICU)的 aPTT 延长患者会通过随访 aPTT 和抗因子 Xa 得到进一步评估。目的:本研究旨在描述接受预防性 SQ-UFH 且有证据表明 aPTT 延长的神经重症患者的 aPTT 和抗因子 Xa 之间的一致性:对2017年6月至2019年6月入住神经重症监护室的成人患者进行回顾性病历审查。如果患者接受了 SQ-UFH,且 aPTT 水平和至少一个抗因子 Xa 水平在一小时内分别绘制,则纳入该患者。配对的 aPTT 和抗因子 Xa 之间的一致性采用科恩加权卡帕进行评估:结果:共纳入了 42 名患者,56 次配对 aPTT 和抗因子 Xa 水平。处方最多的 SQ-UFH 方案为每 8 小时 5000 单位(60.7%),抗因子 Xa 水平的中位数(IQR)为 SQ-UFH 用药后 5.7(3.1-10.7)小时。只有 16 对(28.6%)结果一致。分析显示加权卡帕值为 0.09;95% CI [-.05 至 0.22],表明一致性较差:结论:在接受预防性 SQ-UFH 且 aPTT 延长的神经重症患者中,aPTT 和抗因子 Xa 之间的一致性很差。这表明 aPTT 延长可能并非完全由肝素活性驱动,因此有必要进一步评估该人群中凝血病变的机理驱动因素。
Concordance Between Active Partial Thromboplastin Time and Anti-Factor Xa Assays in Neurocritically Ill Patients Receiving Subcutaneous Heparin Prophylaxis.
Background: Laboratory monitoring is not recommended when subcutaneous unfractionated heparin (SQ-UFH) is administered at prophylactic doses. However, aPTT prolongation and associated hemorrhage has been reported in the neurocritically ill. At our institution, Neuroscience Intensive Care Unit (Neuro-ICU) patients with prolonged aPTT are further evaluated with a follow up aPTT and anti-factor Xa.
Purpose: The purpose of this study was to describe concordance between aPTT and anti-factor Xa in neurocritically ill patients receiving prophylactic SQ-UFH with evidence of aPTT prolongation.
Methods: A retrospective chart review of adult patients admitted to the Neuro-ICU from June 2017 to June 2019 was performed. Patients were included if they received SQ-UFH with aPTT levels and at least one anti-factor Xa level drawn within one hour of each other. Concordance between paired aPTT and anti-factor Xa was evaluated using Cohen's weighted kappa.
Results: Forty two patients with 56 paired aPTT and anti-factor Xa levels were included. The most prescribed SQ-UFH regimen was 5000 units every 8 hours (60.7%) and anti-factor Xa levels were drawn a median (IQR) of 5.7 (3.1-10.7) hours after the SQ-UFH dose. Only 16 (28.6%) pairs were in concordance. The analysis showed a weighted kappa of .09; 95% CI [-.05 to .22] indicating poor agreement.
Conclusions: In neurocritically ill patients receiving prophylactic SQ-UFH with aPTT prolongation, there was poor concordance between aPTT and anti-factor Xa. This suggests that aPTT prolongation may not be solely driven by heparin activity and further evaluation of mechanistic drivers for coagulopathy in this population is necessary.